BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Letavic MA, Bonaventure P, Carruthers NI, Dugovic C, Koudriakova T, Lord B, Lovenberg TW, Ly KS, Mani NS, Nepomuceno D, Pippel DJ, Rizzolio M, Shelton JE, Shah CR, Shireman BT, Young LK, Yun S. Novel Octahydropyrrolo[3,4- c ]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate. J Med Chem 2015;58:5620-36. [DOI: 10.1021/acs.jmedchem.5b00742] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Boss C, Roch C. Orexin research: patent news from 2016. Expert Opinion on Therapeutic Patents 2017;27:1123-33. [DOI: 10.1080/13543776.2017.1344221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
2 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
3 Hoyer D, Jacobson LH. Orexin Receptor Antagonists. Curr Sleep Medicine Rep 2017;3:342-53. [DOI: 10.1007/s40675-017-0099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Futamura A, Nozawa D, Araki Y, Tamura Y, Tokura S, Kawamoto H, Tokumaru Y, Kakihara S, Aoki T, Ohtake N. Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide. Bioorganic & Medicinal Chemistry 2017;25:5203-15. [DOI: 10.1016/j.bmc.2017.07.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Bai P, Liu Y, Xu Y, Striar R, Yuan G, Afshar S, Langan AG, Rattray AK, Wang C. Synthesis and characterization of a new Positron emission tomography probe for orexin 2 receptors neuroimaging. Bioorg Chem 2022;123:105779. [PMID: 35397430 DOI: 10.1016/j.bioorg.2022.105779] [Reference Citation Analysis]
6 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gentile TA, Simmons SJ, Watson MN, Connelly KL, Brailoiu E, Zhang Y, Muschamp JW. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine. Neuropsychopharmacology 2018;43:1001-9. [PMID: 28741623 DOI: 10.1038/npp.2017.158] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
8 Mieda M. The roles of orexins in sleep/wake regulation. Neuroscience Research 2017;118:56-65. [DOI: 10.1016/j.neures.2017.03.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
9 Pennington LD, Aquila BM, Choi Y, Valiulin RA, Muegge I. Positional Analogue Scanning: An Effective Strategy for Multiparameter Optimization in Drug Design. J Med Chem 2020;63:8956-76. [PMID: 32330036 DOI: 10.1021/acs.jmedchem.9b02092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
10 Vanda D, Zajdel P, Soural M. Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases. European Journal of Medicinal Chemistry 2019;181:111569. [DOI: 10.1016/j.ejmech.2019.111569] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
11 Wu YJ, Meanwell NA. Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design. J Med Chem 2021;64:9786-874. [PMID: 34213340 DOI: 10.1021/acs.jmedchem.1c00790] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Marson CM. Saturated Heterocycles with Applications in Medicinal Chemistry. Heterocyclic Chemistry in the 21st Century - A Tribute to Alan Katritzky. Elsevier; 2017. pp. 13-33. [DOI: 10.1016/bs.aihch.2016.03.004] [Cited by in Crossref: 11] [Article Influence: 2.2] [Reference Citation Analysis]
13 Wei H, Hu Q, Ma Y, Wei L, Liu J, Shi M, Wang F. Highly N 2 -Regioselective TsOH-Catalyzed Olefin Hydroamination: Metal-Free Synthesis of N2 -Alkyl-1,2,3-triazoles. Asian J Org Chem 2017;6:662-5. [DOI: 10.1002/ajoc.201700045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
14 Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, Fraser I, Lord B, Shoblock J, Welty N, Chaplan SR, Aguilar Z, Halter R, Ndifor A, Koudriakova T, Rizzolio M, Letavic M, Carruthers NI, Lovenberg T, Dugovic C. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J Pharmacol Exp Ther 2015;354:471-82. [PMID: 26177655 DOI: 10.1124/jpet.115.225466] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
15 Feskov IO, Chernykh AV, Kuchkovska YO, Daniliuc CG, Kondratov IS, Grygorenko OO. 3-((Hetera)cyclobutyl)azetidines, “Stretched” Analogues of Piperidine, Piperazine, and Morpholine: Advanced Building Blocks for Drug Discovery. J Org Chem 2019;84:1363-71. [DOI: 10.1021/acs.joc.8b02822] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
16 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
17 Boss C, Roch C. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934). Expert Opin Ther Pat 2016;26:409-15. [PMID: 26593218 DOI: 10.1517/13543776.2016.1124087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Bai Q, Pérez-Sánchez H, Shi Z, Li L, Shi D, Liu H, Yao X. Computational studies on horseshoe shape pocket of human orexin receptor type 2 and boat conformation of suvorexant by molecular dynamics simulations. Chem Biol Drug Des 2018;92:1221-31. [PMID: 29450984 DOI: 10.1111/cbdd.13181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
19 Deflorian F, Perez-Benito L, Lenselink EB, Congreve M, van Vlijmen HWT, Mason JS, Graaf C, Tresadern G. Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation. J Chem Inf Model 2020;60:5563-79. [PMID: 32539374 DOI: 10.1021/acs.jcim.0c00449] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
20 Maehara S, Yuge N, Higashi C, Ota T, Furukawa J, Takeuchi T. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878. Neuropsychopharmacol Rep 2020;40:182-9. [PMID: 32337858 DOI: 10.1002/npr2.12105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Brooks S, Jacobs GE, de Boer P, Kent JM, Van Nueten L, van Amerongen G, Zuiker R, Kezic I, Luthringer R, van der Ark P, van Gerven JM, Drevets W. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J Psychopharmacol 2019;33:202-9. [DOI: 10.1177/0269881118822258] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
22 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
23 Boss C, Gatfield J, Brotschi C, Heidmann B, Sifferlen T, von Raumer M, Schmidt G, Williams JT, Treiber A, Roch C. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. ChemMedChem 2020;15:2286-305. [PMID: 32937014 DOI: 10.1002/cmdc.202000453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Chen C, Lu X, Holland MC, Lv S, Ji X, Liu W, Liu J, Depre D, Westerduin P. Synthesis of 2-Substituted 1,2,3-Triazoles via an Intramolecular N - N Bond Formation: Synthesis of 2-Substituted 1,2,3-Triazoles via an Intramolecular N - N Bond Formation. Eur J Org Chem 2020;2020:548-51. [DOI: 10.1002/ejoc.201901519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Stump CA, Cooke AJ, Bruno J, Cabalu TD, Gotter AL, Harell CM, Kuduk SD, Mcdonald TP, O’brien J, Renger JJ, Williams PD, Winrow CJ, Coleman PJ. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology. Bioorganic & Medicinal Chemistry Letters 2016;26:5809-14. [DOI: 10.1016/j.bmcl.2016.10.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
26 Wu S, Sun Y, Hu Y, Zhang H, Hou L, Liu X, Li Y, He H, Luo Z, Chen Y, Wang Y, Shi W, Shen L, Cao C, Liang W, Xu Q, Lv Q, Lan J, Li J, Chen S. Discovery of novel substituted octahydropyrrolo[3,4- c ]pyrroles as dual orexin receptor antagonists for insomnia treatment. Bioorganic & Medicinal Chemistry Letters 2017;27:1458-62. [DOI: 10.1016/j.bmcl.2017.01.075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]